Results 71 to 80 of about 459,821 (133)
NGLY1 deficiency is a rare inherited disorder caused by mutations in the NGLY1 gene encoding N-glycanase 1 that is a hydrolase for N-linked glycosylated proteins. An induced pluripotent stem cell (iPSC) line was generated from the dermal fibroblasts of a
Shu Yang +10 more
doaj +1 more source
Comprehensive Pan‐Cancer Analysis of TRNT1 as a Potential Biomarker for Breast Cancer
ABSTRACT TRNT1, an RNA nucleotide transferase, plays a critical role in cellular processes and may be involved in cancer. However, its role in cancer has not been fully explored. This study aims to explore the potential significance of TRNT1 in cancer, particularly in breast cancer (BC) progression and prognosis.
Xinwei Li, Yue Meng, Bing Gu
wiley +1 more source
The cytosolic PNGase (peptide:N-glycanase), also known as peptide-N4-(N-acetyl-β-glucosaminyl)-asparagine amidase, is a well-conserved deglycosylation enzyme (EC 3.5.1.52) which catalyzes the non-lysosomal hydrolysis of an N(4)-(acetyl-β-d-glucosaminyl ...
Lu, Guanting +7 more
core +1 more source
N-glycanase 1 (NGLY1) is an essential enzyme involved in the deglycosylation of misfolded glycoproteins through the endoplasmic reticulum (ER)-associated degradation (ERAD) pathway, which could hydrolyze N-glycan from N-glycoprotein or N-glycopeptide in ...
Yuxin Zhang +12 more
core +1 more source
Sugar coating autophagy: exploring the links between the inhibition of NGLY1 (N-glycanase 1) and autophagy induction [PDF]
The cytosolic enzyme NGLY1 (N-glycanase 1) is a central mediator of glycoprotein catabolism. The enzyme acts to cleave N-linked glycans from modified substrate asparagine residues prior to degradation of misfolded proteins by the proteasome, playing a ...
Sarah Ann Allman +4 more
core +1 more source
Clinical and Molecular Features of Patients With Congenital Disorders of Glycosylation in Japan
ABSTRACT Congenital disorders of glycosylation (CDG) are a heterogeneous group of diseases caused by defects in various steps of the glycosylation pathway. There are over 200 known human glycosylation‐related disorders. Many of these defects lead to multisystemic manifestations, commonly involving the central nervous system, with symptoms ranging from ...
Nobuhiko Okamoto +2 more
wiley +1 more source
REGULATION OF NORMAL CEREBRAL DEVELOPMENT AND MELANOCYTIC ONCOPATHOLOGY BY N-GLYCANASE 1 [PDF]
The congenital disorders of glycosylation (CDG) are a group of diseases with inborn errors in metabolism that result from the improper glycosylation of necessary biological molecules.
Lin, Victor J.T.
core +2 more sources
Antigen presentation of post‐translationally modified peptides in major histocompatibility complexes
T cells recognize pathogens and malignantly transformed cells through antigen presentation on major histocompatibility complex molecules. Post‐translational modifications (PTMs) of proteins can alter the peptides presented, influencing immune recognition and disease.
Alexine S de Wit +2 more
wiley +1 more source
N-glycanase 1 (NGLY1) Deficiency is a rare monogenic multi-system disorder first described in 2014. NGLY1 is evolutionarily conserved in model organisms, including theDrosophila melanogasterNGLY1 homolog,Pngl.
Joshua D. Mast +3 more
core +1 more source
Genetic counseling for congenital disorders of glycosylation (CDG)
Abstract Congenital disorders of glycosylation (CDGs) are a genetically and clinically diverse group of disorders that arise as a result of defects within glycosylation synthetic pathways. CDGs are caused by pathogenic variants in many different genes in the glycosylation network.
Tara Weixel +2 more
wiley +1 more source

